Gene interactions and pathways from curated databases and text-mining

◀ Back to FKBP7

BCL2 — MTOR

Text-mined interactions from Literome

Kasper et al., Curr Opin Oncol 2007 (Sarcoma) : Included are recent developments in targeted therapy, focusing on the following : antiangiogenic and immunomodulatory drugs ( e.g. anti-cytotoxic T lymphocyte associated antigen-4 monoclonal antibody ), Bcl-2 antisense therapy, raf kinase and mammalian target of rapamycin inhibition , heat shock protein modulators, minor groove binders and other agents being developed
Guo et al., Zhonghua Xue Ye Xue Za Zhi 2012 (Precursor Cell Lymphoblastic Leukemia-Lymphoma) : Oridonin inhibited activation of ABL kinase and its downstream Akt/mTOR , Raf/MEK/ERK and STAT5 signaling pathways, which were constitutively activated in SUP-B15 cell line, down-regulated the level of anti- apoptotic protein Bcl-2 and up-regulated the expression of pro-apoptotic protein Bax
Asnaghi et al., Oncogene 2004 : Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt
Tirado et al., Oncogene 2005 : Transient transfection studies using kinase-dead and rapamycin-resistant forms of mTOR demonstrated that only the downregulation of Bcl-xL was caused by the mTOR inhibitory action of rapamycin, which prevented cap dependent translation initiation, whereas Bax upregulation was induced by rapamycin through a mechanism independent of its mTOR inhibitory activity
Ramanathan et al., Proc Natl Acad Sci U S A 2009 : Bcl-xl, but not VDAC1, is a kinase substrate for mTOR in vitro, and mTOR regulates the association of Bcl-xl with mTOR
Kasper , Rev Recent Clin Trials 2007 (Sarcoma) : Moreover, we give an overview on the emerging compounds for patients with soft tissue sarcoma including recent developments of targeted therapy focusing on antiangiogenic and immunomodulatory drugs, Bcl-2 antisense therapy, raf kinase and mTOR inhibition , minor groove binders, and other agents being developed
Rahmani et al., Cancer Res 2013 (Leukemia, Myeloid) : PI3K/mTOR inhibitors markedly downregulated Mcl-1 but increased Bim binding to Bcl-2/Bcl-xL ; the latter effect was abrogated by ABT-737 ... PI3K/mTOR inhibitors markedly downregulated Mcl-1 but increased Bim binding to Bcl-2/Bcl-xL ; the latter effect was abrogated by ABT-737